Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on minimally invasive, high-definition EEG, ablation, drug delivery and brain stimulation solutions for neurological disorders, NeuroOne uses its SEC reports to present detailed information on its financial condition, operations, risks and material events.
Here you can review NeuroOne’s current reports on Form 8-K, which the company uses to announce events such as quarterly and annual financial results, preliminary revenue figures, FDA 510(k) clearances for devices like the OneRF Trigeminal Nerve Ablation System, capital raising activities and notices related to Nasdaq listing requirements. These filings often incorporate or reference press releases that describe product performance, regulatory milestones and developments in programs including the OneRF Ablation System, spinal cord stimulation initiatives and sEEG-based drug delivery.
In addition to 8-Ks, investors can consult NeuroOne’s periodic reports on Forms 10-Q and 10-K (when available) for comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures tied to its neuromodulation and surgical appliance business. The company has also filed updates related to its at-the-market offering program, distribution agreements and other capital markets activities, which are documented in its SEC submissions.
Stock Titan enhances these NMTC filings with AI-powered summaries that highlight key points, such as revenue trends, gross margin changes, cash position commentary, regulatory updates and listing compliance discussions. Users can quickly identify items like FDA clearance announcements, preliminary annual revenue disclosures and Nasdaq minimum bid price notices, then drill into the full documents for deeper analysis. This page is designed to help investors, analysts and other interested readers efficiently navigate NeuroOne’s official SEC record.
Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach disclosed beneficial ownership of 4,000,000 common shares of NeuroOne Medical Technologies, representing 8.03% of the company’s common stock. The filing states Bleichroeder LP is an investment adviser and that these shares are held in the ordinary course of business for its clients.
The reporting persons report sole voting and sole dispositive power over the 4,000,000 shares and no shared voting or dispositive power. The filing also notes the stake was not acquired to change or influence control of the issuer and that client beneficiaries retain rights to dividends and sale proceeds.
NeuroOne Medical Technologies reported growing product sales and improved liquidity for the period ended June 30, 2025. Product revenue increased to $1.70 million in the quarter and $6.36 million year-to-date, while the Company also recognized $3.0 million of license revenue from an amended distribution agreement with Zimmer, which was recorded in the nine months ended June 30, 2025. Total assets were $10.82 million and cash and cash equivalents rose to $8.04 million, up from $1.46 million at September 30, 2024, largely reflecting an April 2025 equity financing that generated approximately $8.24 million of net proceeds.
Despite revenue gains, NeuroOne reported a net loss of $1.50 million for the quarter and $1.99 million for the nine months, with an accumulated deficit of $76.99 million. The Company reduced its warrant liability from $2.14 million to $1.04 million, and notes continued concentration risk with one customer accounting for the majority of product sales. Management states available cash plus anticipated Zimmer-related revenue and planned expense reductions should fund operations for at least twelve months, but additional financing may be required thereafter.
NeuroOne Medical Technologies Corporation filed a Form 8-K reporting a material event by submitting a Press Release dated
Sio Capital Management, LLC reported beneficial ownership of 3,523,663 shares of NeuroOne Medical Technologies Corp common stock, equal to 7.07% of the outstanding shares (based on 49,817,835 shares outstanding as disclosed by the company). Sio holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power.
The filing states Sio acts as a registered investment adviser to funds that are the record owners of the shares and includes a disclosure that the GP and Michael Castor may be deemed to control the voting and dispositive decisions, although such beneficial ownership is expressly disclaimed. The filing also certifies the securities are held in the ordinary course of business and not to influence control of the issuer.
NeuroOne Medical Technologies Corp. (NMTC) – insider Form 4 filed 07/02/2025
CEO, President and Director David A. Rosa reported one transaction dated 06/30/2025. The filing shows a disposition of 2,458 common shares at $0.678 per share under Transaction Code “F,” which, per SEC definitions, denotes shares withheld to cover taxes or exercise costs rather than an open-market sale. After the transaction, Rosa’s direct ownership stands at 1,158,831 shares.
The sale amounts to roughly 0.2 % of his reported direct holdings, indicating that the executive continues to hold a substantial equity stake and remains materially aligned with shareholders.
Form 4 filing overview: On 06/23/2025, NeuroOne Medical Technologies Corp. (NMTC) director Jeffrey S. Mathiesen received an option to purchase 50,000 shares of common stock at an exercise price of $0.662 per share. The option vests in twelve equal monthly installments over one year and carries an expiration date of 06/23/2035. Following the grant, Mathiesen now beneficially owns 50,000 derivative securities directly.
No open-market purchases or sales of common shares were reported, and no changes to previously held positions were disclosed. The transaction appears to be standard board compensation designed to align the director’s interests with shareholders while creating only modest potential dilution.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
